Attention A T users. To access the menus on this page please perform the following steps.
1. Please switch auto forms mode to off.
2. Hit enter to expand a main menu option (Health, Benefits, etc).
3. To enter and activate the submenu links, hit the down arrow.
You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.
Locator
Contact
Search
Search
VA »
Health Care »
MIRECC / CoE
» VISN 4 MIRECC
»
VISN 4 MIRECC Philadelphia Investigators and Mentors - Henry Kranzler, M.D.
MIRECC / CoE
Menu
VISN 4 MIRECC Philadelphia Investigators and Mentors - Henry Kranzler, M.D.
- Henry Kranzler, M.D.
- Email: henry.kranzler@va.gov; kranzler@mail.med.upenn.edu
- MIRECC Role(s): Investigator, Fellowship Director (Psychiatry)
- Bio: Dr. Kranzler is a 1982 graduate of Robert Wood Johnson Medical School, Rutgers University. He completed a psychiatric residency and NIAAA Postdoctoral Fellowship in Alcohol Studies at the University of Connecticut School of Medicine. He is a Distinguished Fellow of the American Academy of Addiction Psychiatry and an Emeritus Fellow of the American College of Neuropsychopharmacology. Dr. Kranzler's research has been continuously supported since 1987 by grants from NIAAA, NIDA, and NCI. He has authored or co-authored more than 500 journal articles, book chapters, and other publications. He is a frequent journal reviewer, a member of the editorial boards of three journals, and Editor of Alcoholism: Clinical and Experimental Research, the official journal of the Research Society on Alcoholism. Dr. Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania.
- Click here to download a copy of Dr. Kranzler's CV.
- Research Interests: Dr. Kranzler’s research focuses on the genetics and pharmacological treatment of alcohol and drug dependence and common co-morbid psychiatric disorders. In addition, this work focuses on clinical trials methodology and the identification of genetic moderators and their mechanism of action in the pharmacological treatment of substance use disorders.
